FANJ
BPMC

Financial Architects (New Jersey)’s Blueprint Medicines BPMC Stock Holding History

Financial Architects (New Jersey)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,300
Closed -$180K – 1342
2018
Q3 		$180K Sell
2,300
-717
-24% -$49.8K 0.03% 327
2018
Q2 		$192K Hold
3,017
– – 0.03% 283
2018
Q1 		$277K Buy
+3,017
New +$260K 0.05% 241

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Financial Architects (New Jersey)'s BPMC Position: Q4 2018 in Review

Financial Architects (New Jersey) sold out of Blueprint Medicines (BPMC) in Q4 2018, closing a stake of 2,300 shares — an estimated $180K sold.

Financial Architects (New Jersey) first reported a position in BPMC in Q1 2018 and held it in 3 quarters. The position peaked at $277K in Q1 2018. 162 funds tracked by Wall St. Rank hold BPMC as of Q4 2018.

  • Financial Architects (New Jersey) reported no remaining Blueprint Medicines position as of Q4 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 2,300 Blueprint Medicines shares in Q4 2018, an estimated $180K.
  • Financial Architects (New Jersey) first reported a position in Blueprint Medicines in Q1 2018 and held it in 3 quarters.
  • Financial Architects (New Jersey)'s Blueprint Medicines position peaked at $277K in Q1 2018.
  • 162 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2018, filed 1 Feb 2019.